MBK Partners’ Bid For AsiaPharm Nears Completion
This article was originally published in PharmAsia News
AsiaPharm's delisting from the Singapore Stock Exchange in February this year has been strongly opposed by some shareholders but the situation could soon change. Martin Currie recently announced it has accepted MBK Partners' takeover offer and will transfer its 5.68 percent stake in AsiaPharm; Templeton Asset Management will also give the nod if MBK raises its bidding price from S$0.725 to S$0.9 per share. However, MBK stands by its current offer which, as of early May, has been accepted by about 77 percent of AsiaPharm's shareholders and the offer deadline of May 24 would not be extended. Industry analysts observe that AsiaPharm investors intend to use the firm as a platform to list its performing subsidiaries in future. (Click here for more - Chinese Language)
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.